Our ambition is to change lives by changing the course of blood cancer.
Latest Updates
Research & Development
Geron announces FDA acceptance of New Drug Application for imetelstat for the treatment of transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (LR-MDS)
Learn moreResearch & Development
Events
Investor Event
Watch the webcasts from Geron’s participation in two investor conferences in April
Geron’s Chairman and Chief Executive Officer, John Scarlett, M.D., hosted a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference and gave a corporate presentation at Stifel’s 2024 Virtual Targeted Oncology Days.
View webcasts here:
Medical Congress
Geron data presentations at NCCN and HOPA 2024 Annual Conferences
Geron presented data at the National Comprehensive Cancer Network (NCCN) Annual Conference and the Hematology/Oncology Pharmacy Association Annual Conference (HOPA).
View the presentations here:
Publications
Research & Development
Imetelstat in patients with lower-risk MDS who have relapsed or are refractory to erythropoiesis-stimulating agents in IMerge phase 3 trial
Platzbecker, et. al.
Research & Development
Continuous Transfusion Independence with Imetelstat in Lower Risk MDS in IMerge Phase 3
Platzbecker, et. al.
Research & Development
Exploring the broad potential of telomerase inhibition across multiple hematologic malignancies
Learn how we’re building on Nobel Prize-winning science
Patients
We are on a mission to extend and enhance lives
Discover more about our commitment to patients
Culture
We see things in ways others do not
Careers